A Fuzzy Spatio-Temporal-based Approach for Activity Recognition

International audienceOver the last decade, there has been a significant deployment of systems dedicated to surveillance. These systems make use of real-time sensors that generate continuous streams of data. Despite their success in many cases, the increased number of sensors leads to a cognitive overload for the operator in charge of their analysis. However, the context and the application requires an ability to react in real-time. The research presented in this paper introduces a spatio-temporal-based approach the objective of which is to provide a qualitative interpretation of the behavior of an entity (e.g., a human or vehicle). The process is formally supported by a fuzzy logic-based approach, and designed in order to be as generic as possible

The role of CD27-CD70-mediated T cell co-stimulation in vasculogenesis, arteriogenesis and angiogenesis

Cardiolog

Around the Van Daele–Schmüdgen Theorem

For a {bounded} non-negative self-adjoint operator acting in a complex, infinite-dimensional, separable Hilbert space H and possessing a dense range R we propose a new approach to characterisation of phenomenon concerning the existence of subspaces M\subset H such that M\capR=M^\perp\capR=\{0\}. We show how the existence of such subspaces leads to various {pathological} properties of {unbounded} self-adjoint operators related to von Neumann theorems \cite{Neumann}--\cite{Neumann2}. We revise the von Neumann-Van Daele-Schm\"udgen assertions \cite{Neumann}, \cite{Daele}, \cite{schmud} to refine them. We also develop {a new systematic approach, which allows to construct for any {unbounded} densely defined symmetric/self-adjoint operator T infinitely many pairs of its closed densely defined restrictions T_k\subset T such that \dom(T^* T_{k})=\{0\} (\Rightarrow \dom T_{k}^2=\{0\}$) k=1,2 and \dom T_1\cap\dom T_2=\{0\}, \dom T_1\dot+\dom T_2=\dom T

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma

Background: In patients with BRAFV600 mutated unresectable stage IIIc or metastatic melanoma, molecular targeted therapy with combined BRAF/MEK-inhibitor vemurafenib plus cobimetinib has shown a significantly improved progression-free survival and overall survival compared to treatment with vemurafenib alone. Nevertheless, the majority of BRAFV600 mutation-positive melanoma patients will eventually develop resistance to treatment. Molecular imaging with 18F-Fluorodeoxyglucose (18F-FDG) PET has been used to monitor response to vemurafenib in some BRAFV600 mutated metastatic melanoma patients, showing a rapid decline of 18F-FDG uptake within 2 weeks following treatment. Furthermore, preliminary results suggest that metabolic alterations might predict the development of resistance to treatment. 18F-Fluoro-3'-deoxy-3'L-fluorothymidine (18F-FLT), a PET-tracer visualizing proliferation, might be more suitable to predict response or resistance to therapy than 18F-FDG. Methods: This phase II, open-label, multicenter study evaluates whether metabolic response to treatment with vemurafenib plus cobimetinib in the first 7 weeks as assessed by 18F-FDG/18F-FLT PET can predict progression-free survival and whether early changes in 18F-FDG/18F-FLT can be used for early detection of treatment response compared to standard response assessment with RECISTv1.1 ceCT at 7 weeks. Ninety patients with BRAFV600E/K mutated unresectable stage IIIc/IV melanoma will be included. Prior to and during treatment all patients will undergo 18F-FDG PET/CT and in 25 patients additional 18F-FLT PET/CT is performed. Histopathological tumor characterization is assessed in a subset of 40 patients to unravel mechanisms of resistance. Furthermore, in all patients, blood samples are taken for pharmacokinetic analysis of vemurafenib/cobimetinib. Outcomes are correlated with PET/CT-imaging and therapy response.

Pyrazolones and amides from b-alkoxy- and b-alkylthio-b-chloroacryloyl chlorides

Conversion of b-alkoxy- and b-alkylthio-b-chloroacryloyl chlorides R1YCCl:CRCOCl (R = H, alkyl, R1 = alkyl and Y = O or S) with amines R2NH2 yields the expected carboxamides R1YCCl:CRCONHR2. Phenylhydrazine reacts with b-alkoxy-b-chloroacryloyl chlorides to give a mixt. of 3-alkoxy-1-phenyl-2-pyrazolin-5-ones and 5-alkoxy-1-phenyl-4-pyrazolin-3-ones. [on SciFinder (R)